Publication
Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia.
Authors not recorded
N Engl J Med2016PMID 27518686PMC5007138stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 3
- drugRuxolitinibcivic_curation1.00
- geneVHLcivic_curation1.00
- variantVHL R200W (c.598C>T)civic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27518686
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| VHL R200W (c.598C>T)1 | ||||||||
| Ruxolitinib | Chuvash PolycythemiaUNRESOLVED | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID1608Homozygous VHL R200W mutations result in a rare congenital polycythemia known as Chuvash polycythemia. Treatment of 3 patients with this disease with the JAK1/2 inhibitor ruxolitinib led to symptomati… (full text at CIViC) PMID 27518686 · Zhou et al., 2016 · Open in CIViC | civic |